Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
Jordana B. Cohen, Thomas C. Hanff, Preethi William, Nancy K. Sweitzer, Nelson R. Rosado‐Santander, C. Medina, Juan E. Rodriguez‐Mori, Nicolás Renna, Tara I. Chang, Vicente Corrales‐Medina, Jaime Andrade‐Villanueva, Alejandro Barbagelata, Roberto Cristodulo-Cortez, Omar A Díaz-Cucho, Jonas Spaak, Carlos E. Alfonso, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo Ayala, Carlos Augusto Castro‐Callirgos, Luz Alicia González-Hernández, Eduardo F Bernales-Salas, Johanna C Coacalla-Guerra, Cynthia Daniela Salinas Herrera, Liliana Nicolosi, Mauro Basconcel, James Brian Byrd, Tiffany Sharkoski, Luis E Bendezú-Huasasquiche, Jesse Chittams, Daniel Edmonston, Charles R. Vasquez, Julio A. Chirinos
Topics & Concepts
DiscontinuationMedicineCoronavirus disease 2019 (COVID-19)Renin–angiotensin systemOpen label2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Prospective cohort studyClinical trialInternal medicineIntensive care medicineVirologyBlood pressureDiseaseOutbreakInfectious disease (medical specialty)COVID-19 Clinical Research StudiesRenin-Angiotensin System StudiesLong-Term Effects of COVID-19